Journal of NeuroVirology

, Volume 18, Issue 5, pp 388–399

Antiretroviral neurotoxicity



Combination antiretroviral therapy (CART) has proven to effectively suppress systemic HIV burden, however, poor penetration into the central nervous system (CNS) provides incomplete protection. Although the severity of HIV-associated neurocognitive disorders (HAND) has been reduced, neurological disease is expected to exert an increasing burden as HIV-infected patients live longer. Strategies to enhance penetration of antiretroviral compounds into the CNS could help to control HIV replication in this reservoir but also carries an increased risk of neurotoxicity. Efforts to target antiretroviral compounds to the CNS will have to balance these risks against the potential gain. Unfortunately, little information is available on the actions of antiretroviral compounds in the CNS, particularly at concentrations that provide effective virus suppression. The current studies evaluated the direct effects of 15 antiretroviral compounds on neurons to begin to provide basic neurotoxicity data that will serve as a foundation for the development of dosing and drug selection guidelines. Using sensitive indices of neural damage, we found a wide range of toxicities, with median toxic concentrations ranging from 2 to 10,000 ng/ml. Some toxic concentrations overlapped concentrations currently seen in the CSF but the level of toxicity was generally modest at clinically relevant concentrations. Highest neurotoxicities were associated with abacavir, efavarenz, etravirine, nevaripine, and atazanavir, while the lowest were with darunavir, emtracitabine, tenofovir, and maraviroc. No additive effects were seen with combinations used clinically. These data provide initial evidence useful for the development of treatment strategies that might reduce the risk of antiretroviral neurotoxicity.


HIV Dementia Neurons Therapy Treatment 


  1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799PubMedCrossRefGoogle Scholar
  2. Bartlett JC, Lane HC (2012) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Office of AIDS Research, pp 1–166.
  3. Bellizzi MJ, Lu SM, Masliah E, Gelbard HA (2005) Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J Clin Invest 115:3185–3192PubMedCrossRefGoogle Scholar
  4. Bressani RF, Nowacek AS, Singh S, Balkundi S, Rabinow B, McMillan J, Gendelman HE, Kanmogne GD (2011) Pharmacotoxicology of monocyte–macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicol 5:592–605.CrossRefGoogle Scholar
  5. Ciccosanti F, Corazzari M, Soldani F, Matarrese P, Pagliarini V, Iadevaia V, Tinari A, Zaccarelli M, Perfettini JL, Malorni W, Kroemer G, Antinori A, Fimia GM, Piacentini M (2010) Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients. Antivir Ther 15:377–390PubMedCrossRefGoogle Scholar
  6. Dilley JW, Schwarcz S, Loeb L, Hsu L, Nelson K, Scheer S (2005) The decline of incident cases of HIV-associated neurological disorders in San Francisco, 1991–2003. AIDS 19:634–635PubMedCrossRefGoogle Scholar
  7. Divi RL, Einem TL, Fletcher SL, Shockley ME, Kuo MM, St Claire MC, Cook A, Nagashima K, Harbaugh SW, Harbaugh JW, Poirier MC (2010) Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs). Toxicol Sci 118:191–201PubMedCrossRefGoogle Scholar
  8. Greenwood SM, Mizielinska SM, Frenguelli BG, Harvey J, Connolly CN (2007) Mitochondrial dysfunction and dendritic beading during neuronal toxicity. J Biol Chem 282:26235–26244PubMedCrossRefGoogle Scholar
  9. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3–16PubMedCrossRefGoogle Scholar
  10. Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685–708PubMedCrossRefGoogle Scholar
  11. Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, Casaccia P (2010) HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 13:180–189PubMedCrossRefGoogle Scholar
  12. Kline ER, Bassit L, Hernandez-Santiago BI, Detorio MA, Liang B, Kleinhenz DJ, Walp ER, Dikalov S, Jones DP, Schinazi RF, Sutliff RL (2009) Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction. Cardiovasc Toxicol 9:1–12PubMedCrossRefGoogle Scholar
  13. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, Ludaway T, McNaught J, Russ R, Stuart T, Santoianni R (2006) Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 20:675–684PubMedCrossRefGoogle Scholar
  14. Maagaard A, Kvale D (2009) Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother 64:901–909PubMedCrossRefGoogle Scholar
  15. Maagaard A, Holberg-Petersen M, Kollberg G, Oldfors A, Sandvik L, Bruun JN (2006) Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 11:601–608PubMedGoogle Scholar
  16. Mahajan SD, Roy I, Xu G, Yong KT, Ding H, Aalinkeel R, Reynolds J, Sykes D, Nair BB, Lin EY, Prasad PN, Schwartz SA (2010) Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Curr HIV Res 8:396–404PubMedCrossRefGoogle Scholar
  17. Manda VK, Mittapalli RK, Bohn KA, Adkins CE, Lockman PR (2010) Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem 115:1495–1507PubMedCrossRefGoogle Scholar
  18. Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA (1992) Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest 66:285–291PubMedGoogle Scholar
  19. Moyle G (2005) Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 10(Suppl 2):M47–M52PubMedGoogle Scholar
  20. Opii WO, Sultana R, Abdul HM, Ansari MA, Nath A, Butterfield DA (2007) Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)—2′,3′-dideoxycytidine (ddC): relevance to HIV-dementia. Exp Neurol 204:29–38PubMedCrossRefGoogle Scholar
  21. Prabhakar K, Afzal SM, Kumar PU, Rajanna A, Kishan V (2011) Brain delivery of transferrin coupled indinavir submicron lipid emulsions—pharmacokinetics and tissue distribution. Colloids Surf B Biointerfaces 86:305–313PubMedCrossRefGoogle Scholar
  22. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915–1921PubMedCrossRefGoogle Scholar
  23. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74:1260–1266PubMedCrossRefGoogle Scholar
  24. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (2001) HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56:257–260PubMedCrossRefGoogle Scholar
  25. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142PubMedCrossRefGoogle Scholar
  26. Saitoh A, Fenton T, Alvero C, Fletcher CV, Spector SA (2007) Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 51:4236–4242PubMedCrossRefGoogle Scholar
  27. Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA (2008) Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. Antimicrob Agents Chemother 52:2825–2830PubMedCrossRefGoogle Scholar
  28. Saiyed ZM, Gandhi NH, Nair MP (2010) Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood–brain barrier. Int J Nanomedicine 5:157–166PubMedGoogle Scholar
  29. Saksena NK, Smit TK (2005) HAART & the molecular biology of AIDS dementia complex. Indian J Med Res 121:256–269PubMedGoogle Scholar
  30. Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R (2009) Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 5:e1000395PubMedCrossRefGoogle Scholar
  31. Schnell G, Price RW, Swanstrom R, Spudich S (2010) Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol 84:2395–2407PubMedCrossRefGoogle Scholar
  32. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK (2004) Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 78:10133–10148PubMedCrossRefGoogle Scholar
  33. Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R, Suzumura A (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280:10444–10454PubMedCrossRefGoogle Scholar
  34. Venhoff N, Setzer B, Melkaoui K, Walker UA (2007) Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 12:1075–1085PubMedGoogle Scholar
  35. Villa G, Solida A, Moro E, Tavolozza M, Antinori A, De Luca A, Murri R, Tamburrini E (1996) Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. Eur Neurol 36:125–133PubMedCrossRefGoogle Scholar
  36. Wang GJ, Nutter LM, Thayer SA (1997) Insensitivity of cultured rat cortical neurons to mitochondrial DNA synthesis inhibitors: evidence for a slow turnover of mitochondrial DNA. Biochem Pharmacol 54:181–187PubMedCrossRefGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2012

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of North CarolinaChapel HillUSA

Personalised recommendations